Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes
Malignancy · primary immunosuppression in kidney transplant recipients
Low showed no clear difference in all malignancy compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).
1 finding from 1 review
- Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes onlyRR 0.84 [0.54, 1.32]10 studies · 3175 participantsModerate